Trial Profile
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo Controlled Parallel-Group Study to Evaluate the Clinical Efficacy and Safety of Induction Therapy With RPC1063 in Patients With Moderately to Severely Active Ulcerative Colitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Dec 2023
Price :
$35
*
At a glance
- Drugs Ozanimod (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms TOUCHSTONE
- Sponsors Celgene Corporation; Celgene International SARL; Receptos
- 17 Oct 2023 Results of a pooled analysis assessing tolerability and safety of long-term ozanimod treatment from following clinical studies: NCT01647516, NCT02435992, NCT02531126 and NCT02576717 presented at the 31st United European Gastroenterology Week
- 27 Apr 2023 Results assessing tolerability/safety of extended ozanimod 0.92 mg/day treatment in adults with relapsing multiple sclerosis (RMS) or moderately to severely active ulcerative colitis, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
- 27 Oct 2021 Results (n=1158; data cut off date: September 30, 2020) of pooled analysis from UC studies phase 2 and phase 3 assessing the safety of extended exposure to ozanimod HCl 1 mg/day from the Ulcerative Colitis and Relapsing Multiple Sclerosis clinical trials presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021